-
1.发明授权Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists 失效用咪唑血管紧张素II受体拮抗剂治疗慢性肾功能衰竭
公开(公告)号：US5210079A
公开(公告)日：1993-05-11
申请号：US832638
申请日：1992-02-07
IPC分类号： A61K31/415 , C07D233/54 , C07D233/68 , C07D233/70 , C07D233/84 , C07D233/90 , C07D401/06 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/14 , C07D405/04 , C07D405/06 , C07D405/10 , C07D405/14 , C07D409/10 , C07D521/00 , C07F9/6506 , C07F9/6558
CPC分类号： C07D233/64 , A61K31/415 , C07D231/12 , C07D233/56 , C07D233/68 , C07D233/70 , C07D233/84 , C07D233/90 , C07D249/08 , C07D401/06 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/14 , C07D405/04 , C07D405/06 , C07D405/10 , C07D405/14 , C07D409/10 , C07F9/65061 , C07F9/65067 , C07F9/6558
摘要： Substituted imidazoles such as 2-butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxymethyl)imidazole and 2-butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)-methyl]-5-(hydroxymethyl)imidazole and pharmaceutically acceptable salts thereof are useful for treating chronic renal failure, mediated by angiotensin-II.
摘要翻译： 取代的咪唑如2-丁基-4-氯-1 - [（2' - （1H-四唑-5-基）联苯-4-基）甲基] -5-（羟甲基）咪唑和2-丁基-4 - 氯代-1 - [（2'-羧基联苯-4-基） - 甲基] -5-（羟甲基）咪唑及其药学上可接受的盐可用于治疗由血管紧张素II介导的慢性肾功能衰竭。
-
公开(公告)号：US5354867A
公开(公告)日：1994-10-11
申请号：US47883
申请日：1993-04-15
IPC分类号： C07D233/54 , C07D233/68 , C07D233/70 , C07D233/84 , C07D233/90 , C07D401/06 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/14 , C07D405/04 , C07D405/06 , C07D405/10 , C07D405/14 , C07D409/10 , C07D521/00 , C07F9/6506 , C07F9/6558 , C07D401/12 , A61K31/415 , A61K31/495
CPC分类号： C07D233/64 , C07D231/12 , C07D233/56 , C07D233/68 , C07D233/70 , C07D233/84 , C07D233/90 , C07D249/08 , C07D401/06 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/14 , C07D405/04 , C07D405/06 , C07D405/10 , C07D405/14 , C07D409/10 , C07F9/65061 , C07F9/65067 , C07F9/6558
摘要： Substituted imidazoles such as ##STR1## are useful as angiotensin II blockers. These compounds have activity in treating hypertension and congestive heart failure.
摘要翻译： 取代的咪唑如“IMAGE”可用作血管紧张素II阻断剂。 这些化合物具有治疗高血压和充血性心力衰竭的作用。
-
3.发明授权
公开(公告)号：US5254546A
公开(公告)日：1993-10-19
申请号：US900540
申请日：1992-06-18
IPC分类号： A61K31/415 , A61K31/47 , A61K31/495 , A61K31/54 , A61K31/675 , A61K45/06 , A61P7/10 , A61P9/00 , A61P9/12 , A61P13/02 , A61P15/00 , A61P29/00 , A61P43/00 , C07D233/54 , C07D233/64 , C07D233/84 , C07D233/90 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/06 , C07D405/10 , C07D405/12 , C07D405/14 , C07D409/04 , C07D409/06 , C07D409/10 , C07D409/14 , C07F9/6506
CPC分类号： C07D233/64 , C07D233/84 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/04 , C07D409/06 , C07D409/14 , C07F9/65062 , C07F9/65067
摘要： Substituted imidazoles such as ##STR1## which are useful as angiotensin II receptor inhibitors. These compounds have activity in treating hypertension and congestive heart failure.
摘要翻译： 取代的咪唑如“IMAGE”，其可用作血管紧张素II受体抑制剂。 这些化合物具有治疗高血压和充血性心力衰竭的作用。
-
4.发明授权Treatment of central nervous system disorders with pyrazole, pyrrole and triazole angiotensin-II receptor antagonists 失效用吡唑，吡咯和三唑血管紧张素-II受体拮抗剂治疗中枢神经系统疾病
公开(公告)号：US5155126A
公开(公告)日：1992-10-13
申请号：US703032
申请日：1991-05-17
IPC分类号： A61K31/40 , A61K31/41 , A61K31/415 , A61K31/535
CPC分类号： A61K31/535 , A61K31/40 , A61K31/41 , A61K31/415
摘要： Substituted pyrazole, pyrrole and triazole angiotensin-II-1 receptor antagonists and pharmaceutically acceptable salts thereof are useful for treating central nervous system disorders, such as cognitive and learning disorders, mediated by angiotensin-II.
摘要翻译： 取代的吡唑，吡咯和三唑血管紧张素-II-1受体拮抗剂及其药学上可接受的盐可用于治疗由血管紧张素II介导的中枢神经系统疾病，例如认知和学习障碍。
-
5.发明授权Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin 失效通过联合使用因子Xa抑制剂和阿司匹林治疗血栓形成公开(公告)号：US06794412B1
公开(公告)日：2004-09-21
申请号：US09519188
申请日：2000-03-06
申请人： Pancras C. Wong
发明人： Pancras C. Wong
IPC分类号： A61K3119
CPC分类号： A61K31/60 , A61K31/19 , A61K31/42 , A61K31/44 , A61K31/47 , A61K31/715 , A61K38/49 , A61K45/06 , A61K2300/00
摘要： Provided is a method of treating thrombosis in mammals by administering therapeutically effective amounts of a combination of (i) a Factor Xa inhibitor, and (ii) a compound selected from the group consisting of aspirin, TPA, a GPIIb/IIIa antagonist, low molecular weight heparin and heparin, wherein the dose administered for at least one of (i) and (ii) is a subtherapeutic dose. Preferably, the combination of (i) and (ii) provides a synergistic effect.
摘要翻译： 本发明提供了一种治疗有效量的（i）因子Xa抑制剂和（ii）选自阿司匹林，TPA，GPIIb / IIIa拮抗剂，低分子量 重量肝素和肝素，其中给予（i）和（ii）中的至少一种的剂量是次治疗剂量。 优选地，（i）和（ii）的组合提供协同效应。
-
6.发明授权Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders 失效低分子量肝素与血小板聚集抑制剂之间的协同作用，为预防和治疗各种血栓栓塞障碍提供了联合疗法公开(公告)号：US06346517B1
公开(公告)日：2002-02-12
申请号：US09523395
申请日：2000-03-10
申请人： Pancras C. Wong , Shaker A. Mousa
发明人： Pancras C. Wong , Shaker A. Mousa
IPC分类号： A61K31725
CPC分类号： A61K31/727 , A61K31/42 , A61K31/60 , A61K31/715 , A61K39/39541 , A61K45/06 , A61K2039/505 , C07K16/2848 , A61K2300/00
摘要： This invention is directed to a combination therapy comprising the administration of a low molecular weight heparin such as tinzaparin and a platelet GPIIb/IIIa antagonist such as roxifiban for treating, preventing and reducing the risk of thromboembolic disorders.
摘要翻译： 本发明涉及包括施用低分子量肝素如锡扎肝素和血小板GPIIb / IIIa拮抗剂如罗西非班的组合疗法，用于治疗，预防和降低血栓栓塞障碍的风险。
-
7.发明申请ASSAY FOR DIFFERENTIATING COMPOUNDS THAT MODULATE THE EXTRINSIC AND/OR INTRINSIC COAGULATION PATHWAYS 审中-公开用于差异调节外在和/或内在凝血途径的化合物的测定公开(公告)号：US20080026474A1
公开(公告)日：2008-01-31
申请号：US11782660
申请日：2007-07-25
申请人： Xinkang Wang , Mei-Yin Hsu , Pancras C. Wong
发明人： Xinkang Wang , Mei-Yin Hsu , Pancras C. Wong
IPC分类号： G01N33/48
CPC分类号： G01N33/86
摘要： Methods for differentiating compounds that modulate the extrinsic and/or intrinsic coagulation pathways are provided. Also provided are methods for identifying a compound that modulates the extrinsic coagulation pathway. In addition, methods for determining an effective dosage of an anticoagulant in a patient are provided.
摘要翻译： 提供了用于分化调节外在和/或固有凝血途径的化合物的方法。 还提供了用于鉴定调节外在凝血途径的化合物的方法。 此外，提供了确定患者抗凝血剂有效剂量的方法。
-
公开(公告)号：US07018990B2
公开(公告)日：2006-03-28
申请号：US10939767
申请日：2004-09-13
申请人： Pancras C. Wong , Robert M. Knabb
发明人： Pancras C. Wong , Robert M. Knabb
CPC分类号： A61K45/06
摘要： The present application describes methods of using a combination of 1-(3′-aminobenzisoxazol-5′-yl)-3-trifluoromethyl-5-[[4-[(2′-dimethylaminomethyl)imidazol-1′-yl]-2-fluorophenyl]aminocarbonyl]pyrazole-hydrochloric acid salt, a factor Xa inhibitor, and Clopidogrel as anticoagulant agents for treatment of thromboembolic disorders and pharmaceutical compositions containing the same.
摘要翻译： 本申请描述了使用1-（3'-氨基苯并异恶唑-5'-基）-3-三氟甲基-5 - [[4 - [（2'-二甲基氨基甲基）咪唑-1'-基] -2 - 氟苯基]氨基羰基]吡唑盐酸盐，因子Xa抑制剂和氯吡格雷作为治疗血栓栓塞障碍的抗凝血剂和含有这些抗凝血剂的药物组合物。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.026 秒)